182 Chapter 7 Table 1. Patient, treatment and volume information of the included subjects in this study. # Age in years Sex Primary tumor #BMs Total BMs vol in cc Prescribed SRS dose in Gy/1 fr Previous RT In between RT Post-RT systemic therapy Edema vol T0 in cc Edema vol T1 in cc Dexamethasone dose pre-RT in mg/day Dexamethasone dose post-RT In mg/day RT responsea 3 57 F Lung 7 4.3 21 N N N 54.3 21.4 0.0 1.5 Decrease 5 66 M Melanoma 18 0.9 21 Y N Y 12.5 98.8 0.0 0.0 Stable 6 81 M Melanoma 2 7.1 21 N N Y 17.1 155.3 0.0 0.5 Growth 7 62 F Lung 11 11.2 21 N N Y 19.5 1.4 0.0 0.0 Decrease 8 72 M Kidney 1 17.6 18 N N Y 80.1 5.7 4.0 0.0 Decrease 11b 52 F Lung 8 50.6 15 N N Y 29.4 4.7 4.0 0.0 Decrease 18 72 M Lung 2 1.8 21 N N N 13.2 0.4 2.0 0.0 Decrease 23b 74 F Lung 1 3.5 18 N Y N 16.3 56.4 0.5 2.5 Growth 24b 62 M Melanoma 10 1.6 24 N N Y 3.1 4.5 0.0 0.0 Mixed abased on the radiology report of the clinical scan; bno post-radiotherapy CVR maps available. Abbreviations: BMs, brain metastases; F, female; M, male; N, no; RT, radiotherapy; T0, pre-radiotherapy, T1, post-radiotherapy; vol; volume; Y, yes
RkJQdWJsaXNoZXIy MTk4NDMw